arrow
D

Doehner, H.

ulm university
H指数:0
被引数:14

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
LEUKEMIA
IF13.4
2019-02-068
OAAI
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
LEUKEMIA
IF13.4
2017-08-1445
PREAI
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia
LEUKEMIA
IF13.4
2017-06-2352
PREAI
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
2017-05-2640
OAAI
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
LEUKEMIA
IF13.4
2017-01-1850
OAAI
Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group
LEUKEMIA
IF13.4
2017-01-1615
PREAI
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia
2016-12-0926
OAAI
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
LEUKEMIA
IF13.4
2016-11-2446
OAAI
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
LEUKEMIA
IF13.4
2016-10-2417
PREAI
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group
LEUKEMIA
IF13.4
2016-07-0440
OAAI
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

急性髓系白血病中的RUNX1突变与不同的临床病理和遗传特征相关

LEUKEMIA
IF13.4
2016-05-03176
OAAI